Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
Molly B MoravekRafael ConfinoAngela K LawsonKristin N SmithRalph R KazerSusan C KlockWilliam J GradisharJacqueline S JerussMary Ellen PavonePublished in: Breast cancer research and treatment (2021)
FP is safe and effective in breast cancer patients, regardless of receptor status; E2 elevations and the 2-week delay in treatment start are unlikely to be clinically significant. These findings are unique in that our institution does not use concomitant letrozole during stimulation to minimize E2 elevations in breast cancer patients.